For research use only. Not for therapeutic Use.
Miravirsen (SPC-3649) is a potent miR-122 inhibitor and inhibits the biogenesis of miR-122. Miravirsen is a 15-nucleotide locked nucleic acid-modified phosphorothioate antisense oligonucleotide. Miravirsen inhibits HCV replication. Miravirsen can be used in research of HCV infection[1][2].
Miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122[1].
Miravirsen binds to the stem-loop structure of pri- and pre-miR-122 with nanomolar affinity, and inhibits both Dicer- and Drosha-mediated processing of miR-122 precursors[1].
Miravirsen (SPC-3649; 2.5-25 mg/kg; i.v.; daily, for 3 d) inhibits miR-122 activity in mice[2].
| Catalog Number | I045367 |
| CAS Number | 1072874-90-8 |
| Purity | ≥95% |
| Reference | [1]. Luca F R Gebert, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014 Jan;42(1):609-21. [2]. Elmén J, et, al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008 Mar;36(4):1153-62. |
